• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NextFlex, Profusa Unveils Injectable Biosensor for Continuous Oxygen Monitoring in Tissue

by Jasmine Pennic 02/18/2019 Leave a Comment

NextFlex, Profusa Unveils Injectable Biosensor for Continuous Oxygen Monitoring in Tissue

Today at FLEX 2019, integrated biosensor makers Profusa and NextFlex unveiled a skin-worn reader prototype with an injected hydrogel biosensor for continuous oxygen monitoring in tissue. The Lumee™ Oxygen Platform is intended for use in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from continuous monitoring.

Lumee Oxygen Hydrogel Biosensor

 The Lumee Oxygen Hydrogel biosensor, a tiny flexible fiber (3 mm to 5 mm long and approximately 500 microns in diameter) that is placed under the skin with a specially designed injector. The Lumee optical reader measures oxygen levels in the surrounding tissue by exciting the biosensor with light and then measuring the emitted fluorescent light. Profusa’s biosensors fully integrate with the body’s tissue without any metal devices or electronics, avoiding the foreign body response for up to two years. The injectable hydrogel sensor is currently CE Marked in Europe and it is not yet commercially available elsewhere.

Skin-Worn Reader Prototype Details

The skin-worn reader was developed in record time, just in four months, at NextFlex’s research center and fab in San Jose, Calif., since the facility and the team combine expertise in flexible hybrid electronics, engineering, materials science and optics all reside under one roof. NextFlex has taken Profusa’s design work and criteria and pushed them toward a smaller, flexible reality that works in harmony with Profusa’s tissue sensors. With this stage completed and other medical devices in the pipeline, NextFlex is engaged in the application for FDA approval for medical device manufacturing.

“Ten years ago, you couldn’t build a reader that could sense multiple signals and filter out the ‘noise’ of the body’s other signals, all while being small and skin-worn,” said Ben Hwang, CEO of Profusa. “With the latest advancements in flexible hybrid electronics technology, it’s just mature enough to work the way we want — primarily because we selected the right domain expertise partner to work with, namely NextFlex. Rather than managing development across multiple R&D and manufacturing facilities, we found a single place at NextFlex’s Technology Hub, where we could develop our solution in very short time and have the right conversations to move our reader design toward production at scale.”

Tagged With: Biosensors, continuous oxygen monitoring, Continuous Vital Sign Monitoring

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |